Development of vaccines has been a matter of concern for the number of laboratories in India, every year Research labs in India are investing in the process of vaccine development and child immunization in order to ensure maximized health scale. As we are witnessing the era of health revolution, routine child immunization has played a significant role in preventing childhood deaths and disability; thousands of children in India continue to die from vaccine preventable diseases each year. According to a recent report, Hilleman Laboratories will be investing 90 million pounds (nearly Rs 650 crore) in seven years to develop vaccines, including one to treat diarrhea, for which it will conduct research in India.
There are a number of health institutions that are readily preparing immunization chart for children from 1 month to 6 years of age group, this will provided to parents so that not even a single child immunization goes skipped and parents can keep a track deliberately. As per most of the medical institutions over the world, rotavirus diarrhea leads to annual deaths of five to seven lakh children all over the globe, out of which one lakh are in India alone. Therefore, it’s good to be aware about the situations happening in the world rather than becoming a victim of such fatal disease. Other is the name of the disease hepatitis a and hepatitis b, hepatitis A vaccine cost is quite expensive in Indian market, but still you will get it at lesser prices from some of the charitable hospitals and medical institutes. Hepatitis B vaccines are being inclusive in the national vaccination schedule.
An overview has been made about the disease in the conference – Hepatitis B is a disease of the liver caused by Hepatitis B virus (HBV) infection. HBV is transmitted through contact with infected blood or body fluids, unprotected sexual intercourse and the perinatal route but not through casual contact. About two billion people worldwide have been infected with the virus, an estimated 360 million live with chronic infection, and at least 600,000 people die annually from acute or chronic consequences of Hepatitis B, such that Hepatitis B is a major public health problem worldwide.
India has restored its image internationally when it comes to the successful development of vaccines and immunization policy. Vaccine policy of India is not rigid and streamlined the practice vaccines in India, recently in December, 2012 World Health Organization (WHO) has approved the vaccine policy adopted by India. With this approval India became the first country in 2012 to pass the stringent levels of seven indicators that is put forward by the WHO that is made much more stringent every time conducted by a team of 12 international experts headed by a member of WHO.